Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
CNMD
STRONG BUYFLAGCONMED Corporation · Healthcare · United States · $1.3B · Avg Vol: $32M/d
CONMED clears the floor (Q56 V71 M60) but Q56 keeps it off the all-above-60 route, with a 1.4% EPS cut and no corroborating filing. Surgical devices with reasonable value and marginal quality.
COMPANY DESCRIPTION
CONMED Corporation is a global medical technology company specializing in the development and manufacture of surgical devices and equipment for minimally invasive procedures across various specialties. Its core products include solutions for arthroscopy, powered surgical instruments, and advanced energy, which address unmet clinical needs. The company's competitive edge lies in its innovation within niche surgical markets and its established relationships with surgical professionals worldwide.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.0B | 1.2B | 1.3B | 1.4B | 9.6% | 1.4B | 1.4B | 1.4B | 2.1% |
| EPS | -2.68 | 2.10 | 4.29 | 1.52 | -14.9% | 1.78 | 1.44 | 1.56 | 1.4% |
| Shares | 30.5M | 30.8M | 30.9M | 31.0M | +1.6% | 30.1M | — | — | — |
| Debt | 1.1B | 973.8M | 905.8M | 834.9M | -7.5% | 860.9M | — | — | — |
| Equity | 745.5M | 834.2M | 962.7M | 1.0B | 11.5% | — | — | — | — |
| Op CF | 33.4M | 125.3M | 167.0M | 170.7M | 72.3% | 142.6M | — | — | — |
| Inv CF | -249.5M | -20.0M | -13.1M | -21.0M | — | — | — | — | — |
| Fin CF | 225.0M | -110.4M | -151.0M | -135.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of CNMD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| CNMD | CONMED Corporation(you) | $1.3B | 86 | STRONG BUY |
| IRMD | IRADIMED CORPORATION | $1.2B | 78 | BUY |
| AHCO | AdaptHealth Corp. | $1.5B | 79 | BUY |
| IART | Integra LifeSciences Holdings Corporation | $1.5B | 80 | BUY |
| ENOV | Enovis Corporation | $1.6B | 80 | BUY |
| AVNS | Avanos Medical, Inc. | $1.2B | 72 | BUY |
| TCMD | Tactile Systems Technology, Inc. | $620M | 87 | STRONG BUY |
| UFPT | UFP Technologies, Inc. | $1.8B | 75 | BUY |
| BVS | Bioventus Inc. | $799M | 96 | STRONG BUY |
| HAE | Haemonetics Corporation | $3.6B | 89 | STRONG BUY |
Peer medians: ROE -25.6% · P/E 27.9x · Gross margin 50.5%